Key result
PPCM drives reduced LV function and heart failure in pregnant women with no prior CVD.
Why the study?
Despite advances in understanding its molecular and clinical underpinnings, peripartum cardiomyopathy remains a diagnosis of exclusion.
This review provides a comprehensive overview of peripartum cardiomyopathy, highlighting its clinical presentation, incidence, genetic factors, animal models, and potential biomarkers.
Alerts clinicians to PPCM in peripartum women without prior disease; leaves open genetic roles pending prospective studies.
Peripartum cardiomyopathy (PPCM) is a rare, but potentially life-threatening condition that typically presents during the final month of pregnancy, or within the first few months postpartum. PPCM is characterized by a decrease in left ventricular function that leads to heart failure in pregnant women with no previous history of cardiovascular disease, and for which the etiology of heart failure cannot be identified. Despite advances in understanding its molecular and clinical underpinnings, PPCM remains a diagnosis of exclusion. This review provides an overview of PPCM, including discussions on clinical presentation, population incidence, the potential role for genetic mutations, existing animal models, and candidate biomarkers.
No takes yet. Share an insight, caveat, or question.
Goldsmith et al. (2026) studied this question. Peripartum cardiomyopathy (PPCM) leads to reduced left ventricular function and heart failure in pregnant women with no prior cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: